FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)

View source ↗

Summary

The FDA approved a supplemental application for a generic Fluoxetine hydrochloride product from PAI Holdings dba PAI Pharma under ANDA 076015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bulimia Nervosa
• Major Depressive Disorder
• Obsessive-compulsive Disorder
• Panic Disorder
• Premenstrual Dysphoric Disorder

Drugs mentioned

• Fluoxetine hydrochloride (Fluoxetine hydrochloride)

Snippet

SUPPL AP for FLUOXETINE (FLUOXETINE HYDROCHLORIDE)